peptide hormone raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-01 and is reviewed periodically as new material appears.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
The next doubly magic nucleus is now expected to be around 306Ubb, but this nuclide's expected short half-life and low production cross section make its synthesis challenging. Still, the island of stability is expected to exist in this region, and nearer its centre (which has not been approached closely enough yet) some nuclides, such as 291Mc and its alpha- and beta-decay daughters, may be found to decay by positron emission or electron capture and thus move into the centre of the island. Due to the expected high fission barriers, any nucleus in this island of stability would decay exclusively by alpha decay and perhaps some electron capture and beta decay, both of which would bring the nuclei closer to the beta-stability line where the island is expected to be. Electron capture is needed to reach the island, which is problematic because it is not certain that electron capture is a major decay mode in this region of the chart of nuclides. Experiments were done in 2000–2004 at Flerov Laboratory of Nuclear Reactions in Dubna studying the fission properties of the compound nucleus 292Fl by bombarding 244Pu with accelerated 48Ca ions. A compound nucleus is a loose combination of nucleons that have not yet arranged themselves into nuclear shells. It has no internal structure and is held together only by the collision forces between the two nuclei. Results showed how such nuclei fission mainly by expelling doubly magic or nearly doubly magic fragments such as 40Ca, 132Sn, 208Pb, or 209Bi.
== Comparisons with other drugs for type 2 diabetes == A study funded by Novo Nordisk, the U.S. distributor for Repaglinide, compared their product with Nateglinide in "A randomized, parallel-group, open-label, multicenter 16-week clinical trial". They concluded that the two were similar, but "repaglinide monotherapy was significantly more effective than nateglinide monotherapy in reducing HbA1c and FPG values after 16 weeks of therapy."
In late 2014, the Houthis repaired their relationship with Saleh, and with his help they took control of the capital city. The takeover prompted a Saudi-led military intervention to restore the internationally recognized government, leading to an ongoing civil war which included missile and drone attacks against Saudi Arabia and its ally the United Arab Emirates. Following the outbreak of the Gaza war, the Houthis began to fire missiles at Israel and to attack ships off Yemen's coast in the Red Sea, which they say is in solidarity with the Palestinians and aims to facilitate the entry of humanitarian aid into the Gaza Strip. The Houthi movement attracts followers in Yemen by portraying themselves as fighting for economic development and the end of the political marginalization of Zaydi Shias, as well as by promoting regional political–religious issues in its media. The Houthis have a complex relationship with Yemen's Sunnis; the movement has discriminated against Sunnis but has also allied with and recruited them. The Houthis aim to govern all of Yemen and support external movements against the United States, Israel, and Saudi Arabia. Because of the Houthis' ideological background, the conflict in Yemen is widely seen as a front of the Iran–Saudi Arabia proxy war.
== Regulators == Three general classes of regulators of Rho protein signaling have been identified: guanine nucleotide exchange factor (GEFs), GTPase-activating proteins (GAPs) and guanine nucleotide dissociation inhibitors (GDIs). GEFs activate Rho proteins by catalyzing the exchange of GDP for GTP. GAPs control the ability of the GTPase to hydrolyze GTP to GDP, controlling the natural rate of movement from the active conformation to the inactive conformation. GDI proteins form a large complex with the Rho protein, helping to prevent diffusion within the membrane and into the cytosol and thus acting as an anchor and allowing tight spatial control of Rho activation. In human, 82 GEF (71 Dbl-like and 11 DOCK-like ) control positively the activity of Rho members, while 66 GAP proteins control it negatively. Recent work has unveiled important additional regulatory mechanisms: microRNAs regulate post-transcriptional processing of Rho GTPase-encoding mRNAs; palmitoylation and nuclear targeting affect intracellular distribution; post-translational phosphorylation, transglutamination and AMPylation modulate Rho GTPase signaling; and ubiquitination controls Rho GTPase protein stability and turnover. These modes of regulation add to the complexity of the Rho GTPase signaling network and allow precise spatiotemporal control of individual Rho GTPases.
The origins of Cannabis are linked to a Scythian word. The ancient Greeks may have learned of the use of cannabis, which they called κάνναβις, by observing Scythian funerals, during which cannabis was consumed. In Akkadian, cannabis was known as qunubu (𐎯𐎫𐎠𐎭𐏂). The word was adopted in to the Hebrew as qaneh bosem (קָנֶה בֹּשׂם). The Latin term cannabis derived from Greek evolved into Proto-Germanic *xan(a)paz, yielding various Germanic forms (Old Norse hampr, Old English hænep, Old Saxon hanup, Old High German hanaf) and ultimately modern British English "hemp."
Sources: en.wikipedia.org
== Production == Cadmium is a common impurity in zinc ores, and it is most often isolated during the production of zinc. Some zinc ores concentrates from zinc sulfate ores contain up to 1.4% of cadmium. In the 1970s, the output of cadmium was 2.9 kilograms (6.5 lb) per ton of zinc. Zinc sulfide ores are roasted in the presence of oxygen, converting the zinc sulfide to the oxide. Zinc metal is produced either by smelting the oxide with carbon or by electrolysis in sulfuric acid. Cadmium is isolated from the zinc metal by vacuum distillation if the zinc is smelted, or cadmium sulfate is precipitated from the electrolysis solution. The British Geological Survey reports that in 2001, China was the top producer of cadmium with almost one-sixth of the world's production, closely followed by South Korea and Japan.
== Transcendental/reverse dependent origination == Understanding dependent origination is indispensable for realizing nirvana since it leads to insight into how the process of dependent arising can be brought to an end (i.e. nirvana). Since the process of dependent origination always produces suffering, the reversal or deactivation of the sequence is seen by Buddhists as the way to stop the entire process. Traditionally, the reversal of the sequence of the twelve nidanas is explained as leading to the cessation of rebirth and suffering. The early Buddhist texts state that on the arising of wisdom or insight into the true nature of things, dependent origination ceases. Some suttas state that "from the fading and cessation of ignorance without remainder comes the cessation of saṅkhāras..." et cetera (this is said to lead to the cessation of the entire twelve-fold chain in reverse order). According to Jayarava Attwood, while some dependent origination passages (termed lokiya, worldly) "[model] beings trapped in cycles of craving and grasping, birth and death", other passages (termed lokuttara, 'beyond the world') "[model] the process and dynamics of liberation from those same cycles." According to Bodhi, these are also classified as "exposition of the round" (vaṭṭakathā) and "the ending of the round" (vivaṭṭakathā). Beni Barua called these two different kinds of dependent origination "cyclic" and "progressive".
With both P-selectin and ICAM-1 on the substrate, cells attached and rolled, but the presence of ICAM-1 had no effect. However, if a neutrophil chemoattractant was added to the flow stream, it activated GPCR signaling, actin polymerization, and integrin-dependent firm adhesion to ICAM-1. Springer integrated these findings into the “three step paradigm” of leukocyte extravasation (diapedesis), which has become the standard framework for understanding leukocyte trafficking in inflammation. The laboratory of Eugene Butcher, including postdoctoral fellow Uli von Andrian, was working on emigration of leukocytes in vivo at the same time, and discovered that antibody to leukocyte integrins inhibited firm adhesion, but not rolling adhesion, to postcapillary venules at sites of inflammation. Butcher and Springer received the 2004 Crafoord Prize for this work. Springer's paradigm that integrins on leukocytes bind to counter-receptors with Ig-like domains on endothelium was later extended by others to integrin α4β1 binding to vascular cell adhesion molecule-1 (VCAM-1), which is inducible by inflammatory mediators on endothelium, and α4β7 binding to mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is constitutively expressed on mucosal endothelium. At the time that Springer described the three step model, no chemoattractants for peripheral blood lymphocytes that could stimulate emigration were known. Their existence was implied by the ability of pertussis toxin, which modifies the G protein Gαi subunit, to cause lymphocytosis in patients with whooping cough.
In May 2023, the FDA approved the iLet Bionic Pancreas system for people with Type 1 diabetes of six years and older. The device uses a closed-loop system to deliver both insulin and glucagon in response to sensed blood glucose levels. The 4th generation iLet prototype, presented in 2017, is around the size of an iPhone, with a touchscreen interface. It contains two chambers for both insulin and glucagon, and the device is configurable for use with only one hormone, or both. A 440-patient study of type I diabetes ran in 2020 and 2021 using a device configuration that delivered only insulin in comparison to standard of care; device use led to better circulating glucose control (measured by continuous monitoring) and a reduction in glycated hemoglobin (versus no change for the standard of care group). However, the incidence of severe hypoglycemic events was more than 1.5 times higher among device users versus standard care patients. There are several non-commercial, non-FDA approved DIY options, using open source code, including OpenAPS, Loop, and/or AndroidAPS.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.